Contact Us
Drug Search Results
More Filters [+]

Evogliptin

Alternative Names: evogliptin, da-1229, da 1229, da1229
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Brazil | Ecuador | India | Korea | Philippines | Russia

Approved Indications: None

Known Adverse Events: None

Company: Dong-A
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Evogliptin

Countries in Clinic: Canada, Korea, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Aortic Diseases|Aortic Valve Stenosis|Congenital Heart Defects|Heart Valve Diseases|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EVOID-AS

P3

Active, not recruiting

Heart Valve Diseases|Aortic Valve Stenosis|Congenital Heart Defects|Aortic Diseases

2026-05-15

DIP-CAVD

P2

Completed

Congenital Heart Defects|Aortic Diseases|Heart Valve Diseases

2023-02-01

24%
DA1229_DMTD2_III

P3

Completed

Type 2 Diabetes

2022-02-23

63%

Recent News Events

Date

Type

Title

04/15/2024

PubMed

 Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study.

03/02/2024

PubMed

 Evaluation of the Ejection Pressure for Tracking Internal Cracks during Compaction in Bilayer Tablet Formulations Using Experimental and Finite Element Methods.

10/26/2023

PubMed

 The Effect of Compression Pressure on the First Layer Surface Roughness and Delamination of Metformin and Evogliptin Bilayer and Trilayer Tablets.

07/27/2021

News Article

 Deargen Signs Agreement With Sookmyung Women's University Research & Business Development Foundation for Licensing 'NASH Biomarker' Technologies

07/22/2021

News Article

 Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)

07/22/2021

News Article

 Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)

07/07/2021

News Article

 Dipeptidyl Peptidase 4 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions